Antibe Announces Results of 2022 Annual Meeting
September 09 2022 - 4:00PM
Business Wire
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a
clinical-stage company leveraging its hydrogen sulfide platform to
develop next-generation safer therapies that target inflammation,
is pleased to announce the results of its annual meeting of
shareholders (the “Meeting”) held earlier today. All resolutions
outlined in the management information circular were approved.
Detailed results for the election of directors are provided
below:
Director Nominee
Outcome
% For
% Withheld
Robert E. Hoffman
Elected
89.12%
10.88%
Roderick Flower
Elected
94.91%
5.09%
Amal Khouri
Elected
93.51%
6.49%
Dan Legault
Elected
90.14%
9.86%
Walt Macnee
Elected
93.91%
6.09%
Jennifer McNealey
Elected
93.67%
6.33%
John L. Wallace
Elected
94.31%
5.69%
Yung Wu
Elected
94.22%
5.78%
Voting results on all matters voted on at the Meeting have been
filed on SEDAR.
About Antibe Therapeutics Inc. Antibe is a clinical stage
biotechnology company leveraging its proprietary hydrogen sulfide
platform to develop next-generation safer therapies to target
inflammation arising from a wide range of medical conditions. The
Company’s current pipeline includes assets that seek to overcome
the gastrointestinal (“GI”) ulcers and bleeding associated with
nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead
drug, otenaproxesul, is in clinical development as a safer
alternative to opioids and today’s NSAIDs for acute pain. Antibe’s
second pipeline drug, ATB-352, is being developed for a specialized
pain indication. The Company’s anticipated next target is
inflammatory bowel disease (“IBD”), a condition long in need of
safer, more effective therapies. Learn more at antibethera.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220909005529/en/
Antibe Therapeutics Inc. Christina Cameron VP Investor Relations
+1 416-577-1443 christina@antibethera.com
Antibe Therapeutics (TSX:ATE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Antibe Therapeutics (TSX:ATE)
Historical Stock Chart
From Apr 2023 to Apr 2024